Leu72Met polymorphism of GHRL gene decreases susceptibility to type 2 diabetes mellitus in a Mexican population.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101088676 Publication Model: Electronic Cited Medium: Internet ISSN: 1472-6823 (Electronic) Linking ISSN: 14726823 NLM ISO Abbreviation: BMC Endocr Disord Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
      Genetic Predisposition to Disease* ; Polymorphism, Single Nucleotide*; Biomarkers/*analysis ; Diabetes Mellitus, Type 2/*prevention & control ; Ghrelin/*genetics; Adult ; Case-Control Studies ; Diabetes Mellitus, Type 2/epidemiology ; Diabetes Mellitus, Type 2/genetics ; Female ; Follow-Up Studies ; Genotype ; Humans ; Male ; Mexico/epidemiology ; Middle Aged ; Prognosis
    • Abstract:
      Background: Type 2 diabetes mellitus (T2D) is the most frequent type of diabetes. It has a multifactorial etiology, affecting millions of people worldwide. Ghrelin gene (GHRL) encodes the ghrelin peptide, which promotes food intake, induces body weight and adipogenesis. Several single nucleotide polymorphisms (SNPs) in GHRL gene have been associated with metabolic diseases. A protective effect of the Leu72Met (rs696217) polymorphism has been described for T2D in some populations, but this effect seems to depend on the ethnicity of the patients studied.
      Methods: The aim of this study was to investigate the association between the GHRL Leu72Met (rs696217) SNP with the development of T2D and serum ghrelin levels in a Western Mexican population. We performed a case-control study in which we included 284 subjects (159 with previous T2D diagnosis and 125 control subjects (CS)). Leu72Met SNP was genotyped by using PCR-RFLPs technique. Serum ghrelin levels were measured using a commercial enzyme immunoassay. Genotypic and allelic distributions were compared using Chi square test. Student T-test and Mann-Whitney U test were used to compare quantitative variables. Odds ratio (OR) was used to evaluate the association between alleles or genotypes and T2D. Multiple and logistic regression models were performed for adjustment. A two-tailed p-value ≤0.05 was considered statistically significant.
      Results: Leu72Leu genotype was more frequent among T2D compared to CS (p < 0.05). After adjusting for age and body composition, there was a significant protective effect of the 72Met allele for T2D development (OR 0.40 IC 95% 0.23-0.70; p ≤ 0.001). Fasting serum ghrelin levels were lower in T2D than CS (p ≤ 0.0001) irrespective of age, body weight and BMI. No associations were found between genotypes and ghrelin serum levels in our population.
      Conclusions: The GHRL 72Met allele decreases susceptibility for T2D development in a Western Mexican population. Serum ghrelin levels are lower in T2D independently of Leu72Met polymorphism genotype.
    • References:
      J Clin Endocrinol Metab. 2006 Nov;91(11):4657-63. (PMID: 16954159)
      Nat Rev Endocrinol. 2018 Feb;14(2):88-98. (PMID: 29219149)
      J Nutr. 2016 Sep;146(9):1856S-65S. (PMID: 27511932)
      Endocrinol Metab (Seoul). 2017 Jun;32(2):230-240. (PMID: 28555463)
      BMC Genomics. 2015 Dec 21;16:1093. (PMID: 26690364)
      Clin Chim Acta. 2009 Jan;399(1-2):112-6. (PMID: 18848536)
      Diabetes. 2001 Apr;50(4):707-9. (PMID: 11289032)
      Cell Metab. 2006 May;3(5):379-86. (PMID: 16679295)
      J Clin Res Pediatr Endocrinol. 2016 Dec 1;8(4):425-431. (PMID: 27476441)
      J Endocrinol Invest. 2007 Jun;30(6):484-90. (PMID: 17646723)
      Int J Obes Relat Metab Disord. 2004 Mar;28(3):447-50. (PMID: 14724664)
      Ann Med. 2006;38(4):274-9. (PMID: 16754258)
      Int J Equity Health. 2019 Aug 23;18(1):133. (PMID: 31443659)
      Int J Obes (Lond). 2008 Apr;32(4):663-8. (PMID: 18071345)
      Obesity (Silver Spring). 2009 Apr;17(4):745-54. (PMID: 19165163)
      Salud Publica Mex. 2017 May-Jun;59(3):285-298. (PMID: 28902316)
      Prev Med. 2015 Dec;81:445-50. (PMID: 26546108)
      Handb Clin Neurol. 2014;126:211-22. (PMID: 25410224)
      Front Genet. 2018 Nov 14;9:541. (PMID: 30487812)
      Diabet Med. 2005 Sep;22(9):1157-60. (PMID: 16108842)
      Nucleic Acids Res. 1988 Feb 11;16(3):1215. (PMID: 3344216)
      Front Endocrinol (Lausanne). 2019 Aug 08;10:559. (PMID: 31440212)
      Gene. 2013 Apr 1;517(2):179-83. (PMID: 23321590)
      J Diabetes Res. 2016;2016:6989453. (PMID: 27822482)
      Int J Obes (Lond). 2006 Nov;30(11):1609-14. (PMID: 16865101)
      Peptides. 2018 Feb;100:236-242. (PMID: 29412824)
      Metabolism. 2006 Mar;55(3):366-70. (PMID: 16483881)
      Salud Publica Mex. 2018 Jul-Ago;60(4):404-413. (PMID: 30137942)
      Obes Res. 2002 Aug;10(8):782-91. (PMID: 12181387)
      Diabetes. 2010 Sep;59(9):2145-51. (PMID: 20584998)
    • Contributed Indexing:
      Keywords: Ghrelin; Leu72Met; Polymorphism; Type 2 diabetes mellitus
    • Accession Number:
      0 (Biomarkers)
      0 (GHRL protein, human)
      0 (Ghrelin)
    • Publication Date:
      Date Created: 20200724 Date Completed: 20210528 Latest Revision: 20240329
    • Publication Date:
      20240329
    • Accession Number:
      PMC7374978
    • Accession Number:
      10.1186/s12902-020-00596-3
    • Accession Number:
      32698854